TY - JOUR AU - Lee, Kyoung-Hwa AU - Ku, Ja Hyeon PY - 2018 TI - Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors JF - Translational Andrology and Urology; Vol 7, Supplement 6 (December 20, 2018): Translational Andrology and Urology Y2 - 2018 KW - N2 - Bladder cancer is the fourth most common cancer in men, with an estimated diagnosis of 60,490 new cases and 12,240 deaths in the United States in 2017 (1). Nearly 75% of bladder cancer patients are diagnosed with non-muscle invasive bladder cancer (NMIBC), which consists of stages Ta, T1, and carcinoma in situ (CIS). NMIBC is rarely lethal, but 50–70% of patients experience disease recurrence and 10–30% of patients’ progress to life-threatening muscle-invasive bladder cancer (MIBC) (2). UR - https://tau.amegroups.org/article/view/21986